Gilead Sciences Aktie

93,38USD 1,80USD 1,97%
Gilead Sciences für 0 Euro bei ZERO ordern (zzgl. Spreads)
WKN: 885823 / ISIN: US3755581036
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>

Aktionärsstruktur

Inhaber in %
Freefloat 99,90
The Vanguard Group, Inc. 8,98
Vanguard Group, Inc. (Subfiler) 8,80
Capital Research & Management Co. (World Investors) 6,72
Capital Research & Management Co. (World Investors) 6,15
Capital Research & Management Co. (Global Investors) 4,96
State Street Corp. 4,83
BlackRock Fund Advisors 3,82
Vanguard Total Stock Market ETF 3,16
Vanguard 500 Index Fund 2,65
Dodge & Cox 2,65
Wellington Management Co. LLP (Wellington Breakout) 2,64
American Funds Income Fund of America 2,50
BlackRock Institutional Trust Co. NA 2,30
Geode Capital Management LLC 2,21

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2019 2020 2021 2022 2023
Personal am Ende des Jahres 11 800 13 600 14 400 17 000 18 000
Umsatz pro Mitarbeiter in Mio. EUR 1,89 1,81 1,90 1,59 1,50

Bilanz (in Mio. USD) - Aktiva

2019 2020 2021 2022 2023
Summe Umlaufvermögen 30 296 15 996 14 772 14 443 16 085
Summe Anlagevermögen 31 331 52 411 53 180 48 728 46 040
Summe Aktiva 61 627 68 407 67 952 63 171 62 125

Bilanz (in Mio. USD) - Passiva

2019 2020 2021 2022 2023
Summe Fremdkapital 38 977 50 186 46 888 41 962 39 376
Summe Eigenkapital 22 650 18 221 21 064 21 209 22 749
Summe Passiva 61 627 68 407 67 952 63 171 62 125

Adresse

333 Lakeside Drive, 94404 Foster City
Telefon +1 (650) 574-3000
Fax +1 (650) 522-5853
Internet http://www.gilead.com

Management

Adam D. Levy
Executive Director-Investor Relations
Andrew D. Dickinson
Chief Financial Officer
Anthony Welters
Independent Director
Cindy Perettie
Executive Vice President-Kite
Daniel P. O'Day
Chairman & Chief Executive Officer
Deborah H. Telman
Secretary, EVP-Corporate Affairs & General Counsel
Dustin Haines
Vice President & General Manager-Asia 5
Flavius Martin
Executive Vice President-Research
Harish M. Manwani
Independent Director
Jacqueline K. Barton
Independent Director
Jacquie Ross
Head-Investor Relations
Janet Dorling
Senior VP- Intercontinental Region
Javier J. Rodriguez
Independent Director
Jeffrey A. Bluestone
Independent Director
Johanna Mercier
Chief Commercial Officer
Joydeep Ganguly
Senior Vice President-Corporate Operations
Jyoti K. Mehra
Executive Vice President-Human Resources
Kelly A. Kramer
Independent Director
Linda Slanec Higgins
Senior VP-Research & External Innovation
Melissa Grigorieff Koomey
Vice President-Global Commercial Operations
Merdad V. Parsey
Chief Medical Officer
Robert D. Cook
Vice President
Sandra J. Horning
Independent Director
Sandra K. Patterson
SVP, Chief Accounting Officer & Controller
Sarah C. Pope Miksinski
Executive Director-CMC Regulatory Affairs
Stacey Y. Ma
EVP-Pharmaceutical Development & Manufacturing
Ted W. Love
Independent Director
Tomas Cihlar
Vice President-Virology
William Grossman
Senior VP-Oncology Clinical Development